109 related articles for article (PubMed ID: 12942565)
1. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.
Friedberg JW; Neuberg D; Kim H; Miyata S; McCauley M; Fisher DC; Takvorian T; Canellos GP
Cancer; 2003 Sep; 98(5):978-82. PubMed ID: 12942565
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
Djeridane M; Oudard S; Escoffre-Barbe M; Lacotte-Thierry L; Desablens B; Briére J; Dib M; Cassasus P; Ghandour C; Lamy T; Lejeune F; Simon M; Traullé C; Vigier M; Maisonneuve H; Briére J; Colonna P; Andrieu JM
Cancer; 2002 Nov; 95(10):2169-79. PubMed ID: 12412171
[TBL] [Abstract][Full Text] [Related]
3. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
4. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
5. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
6. Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.
Gobbi PG; Broglia C; Merli F; Dell'Olio M; Stelitano C; Iannitto E; Federico M; Bertè R; Luisi D; Molica S; Cavalli C; Dezza L; Ascari E
Cancer; 2003 Dec; 98(11):2393-401. PubMed ID: 14635074
[TBL] [Abstract][Full Text] [Related]
7. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
Schellong G; Dörffel W; Claviez A; Körholz D; Mann G; Scheel-Walter HG; Bökkerink JP; Riepenhausen M; Lüders H; Pötter R; Rühl U;
J Clin Oncol; 2005 Sep; 23(25):6181-9. PubMed ID: 16135485
[TBL] [Abstract][Full Text] [Related]
8. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
9. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
[TBL] [Abstract][Full Text] [Related]
10. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
11. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
[TBL] [Abstract][Full Text] [Related]
12. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
13. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
[TBL] [Abstract][Full Text] [Related]
14. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM
Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259
[TBL] [Abstract][Full Text] [Related]
15. Late pulmonary toxicity after treatment for Hodgkin's disease.
Villani F; De Maria P; Bonfante V; Viviani S; Laffranchi A; Dell'oca I; Dirusso A; Zanini M
Anticancer Res; 1997; 17(6D):4739-42. PubMed ID: 9494599
[TBL] [Abstract][Full Text] [Related]
16. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
17. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
19. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
[TBL] [Abstract][Full Text] [Related]
20. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
